| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $27.3M | — | +5.0% |
| SG&A Expense | $10.6M | — | +10.2% |
| Operating Income | -$187.9M | — | -427.4% |
| Net Income | -$183.4M | — | -492.4% |
| EPS (Basic) | -$0.60 | — | -445.5% |
| EPS (Diluted) | -$0.60 | — | -445.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $47.3M | -36.0% | -33.0% |
| Short-term Investments | $196.5M | -2.8% | -16.0% |
| Current Assets | $253.8M | -11.3% | -19.3% |
| Total Assets | $461.2M | +16.4% | -2.1% |
| Current Liabilities | $26.7M | -6.5% | +4.7% |
| Total Liabilities | $67.7M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$27.4M | — | +13.2% |
| Capital Expenditures | $36K | — | -56.6% |
| Investing Cash Flow | -$243.8M | — | -811.6% |
| Financing Cash Flow | $244.7M | — | — |
| Free Cash Flow | -$27.4M | — | +13.3% |
| -5.6% |
| Stockholders' Equity | $393.5M | +21.0% | -1.5% |